Atara Biotherapeutics (ATRA – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Robert Burns today. The company’s shares closed yesterday at $1.21.
According to TipRanks, Burns is an analyst with an average return of -40.1% and a 12.40% success rate. Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Kineta, and Repare Therapeutics.
In addition to H.C. Wainwright, Atara Biotherapeutics also received a Hold from Mizuho Securities’s Salim Syed in a report issued today. However, on November 2, Mizuho Securities assigned a Buy rating to Atara Biotherapeutics (NASDAQ: ATRA).
See the top stocks recommended by analysts >>
The company has a one-year high of $5.64 and a one-year low of $1.17. Currently, Atara Biotherapeutics has an average volume of 1.18M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics (ATRA) Company Description:
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Read More on ATRA:
- Atara Biotherapeutics files $400M mixed securities shelf
- Atara Biotherapeutics tab-cel deal worth $4-plus per share, says Mizuho
- Atara Biotherapeutics announces restructuring and 30% workforce reduction
- Atara expands global tab-cel partnership up to $640M with Pierre Fabre
- Atara Biotherapeutics reports Q3 EPS (66c), consensus (66c)
